{
    "ticker": "CELUW",
    "name": "Celularity Inc.",
    "description": "Celularity Inc. is a biotechnology company focused on advancing the field of cellular therapies. Founded in 2017, Celularity is dedicated to developing innovative treatments for cancer and degenerative diseases through its proprietary platform, which utilizes placental-derived cells. The company\u2019s core mission is to harness the unique properties of these cells to create therapies that can improve patient outcomes and offer new hope in the treatment of complex diseases. Celularity's lead product candidates include CYNK-001, an allogeneic natural killer (NK) cell therapy aimed at treating various forms of cancer. The company is also exploring other applications of its advanced cellular technologies, including immunotherapy and regenerative medicine. With a strong pipeline of clinical programs and a commitment to research and development, Celularity is positioned at the forefront of the rapidly evolving field of cell-based therapies. The company is headquartered in Warren, New Jersey, and is committed to ethical practices in its research and commercialization efforts, ensuring that its therapies are not only effective but also safe and accessible to patients.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Warren, New Jersey, USA",
    "founded": "2017",
    "website": "https://www.celularity.com",
    "ceo": "Robert Hariri",
    "social_media": {
        "twitter": "https://twitter.com/CelularityInc",
        "linkedin": "https://www.linkedin.com/company/celularity/"
    },
    "investor_relations": "https://ir.celularity.com",
    "key_executives": [
        {
            "name": "Robert Hariri",
            "position": "CEO"
        },
        {
            "name": "Andrew D. Pecora",
            "position": "CMO"
        }
    ],
    "product_categories": [
        {
            "category": "Cellular Therapies",
            "products": [
                "CYNK-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Celularity Inc. | Innovating Cellular Therapies for Cancer Treatment",
        "meta_description": "Explore Celularity Inc., a leader in biotechnology focused on cellular therapies. Learn about their innovative treatments for cancer and degenerative diseases.",
        "keywords": [
            "Celularity",
            "Cellular Therapies",
            "Biotechnology",
            "Cancer Treatment",
            "Immunotherapy",
            "Regenerative Medicine"
        ]
    },
    "faq": [
        {
            "question": "What is Celularity known for?",
            "answer": "Celularity is known for its innovative cellular therapies derived from placental cells aimed at treating cancer and degenerative diseases."
        },
        {
            "question": "Who is the CEO of Celularity?",
            "answer": "Robert Hariri is the CEO of Celularity Inc."
        },
        {
            "question": "Where is Celularity headquartered?",
            "answer": "Celularity is headquartered in Warren, New Jersey, USA."
        },
        {
            "question": "What are Celularity's main products?",
            "answer": "Celularity's main product is CYNK-001, a natural killer cell therapy for cancer treatment."
        },
        {
            "question": "When was Celularity founded?",
            "answer": "Celularity was founded in 2017."
        }
    ],
    "competitors": [
        "CRIS",
        "ADPT",
        "NKLA",
        "EDIT"
    ],
    "related_stocks": [
        "NVAX",
        "BMY",
        "AMGN",
        "GILD"
    ]
}